| ［1］ |
Gorelick PB，Scuteri A，Black SE，et al.Vascular contributions to cognitive impairment and dementia： a statement for healthcare professionals from the american heart association/american stroke association.Stroke，2011，42（9）：2672-2713.
|
| ［2］ |
Christov A，Ottman T，Hamdheydari L，et al.Structural changes in Alzheimer’s disease brain microvessels. Curr Alzheimer Res，2008，5（4）：392-395.
|
| ［3］ |
Park KW，Jin BK.Thrombin-induced oxidative stress contributes to thedeathof hippocampal neurons：role of neuronal NADPH oxidase.JNeurosciRes，2008，86（5）：1053-1063.
|
| ［4］ |
Rao HV，Thirumangalakudi L，Grammas P. Cyclin C and cyclin dependent kinases 1，2 and 3 in thrombin-induced neuronal cell cycleprogressionandapoptosis.NeurosciLett，2009，450（3）：347-350.
|
| ［5］ |
Huang C，Ma R，Sun S，et al. JAK2-STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro.JNeuroimmunol，2008，204（1-2）：118-125.
|
| ［6］ |
HuangCF，LiG，MaR，etal.Thrombin-inducedmicroglialactivation contributes to the degeneration of nigral dopaminergic neurons in vivo.NeurosciBull，2008，24（2）：66-72.
|
| ［7］ |
Choi MS，Kim YE，Lee WJ，et al.Activation of protease-activated receptor1 mediates induction of matrix metalloproteinase-9 by thrombin in rat primary astrocytes. Brain Res Bull，2008，76（4）：368-375.
|
| ［8］ |
Bell RD，Winkler EA，Sagare AP，et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain andduringaging.Neuron，2010，68（3）：409-427.
|
| ［9］ |
KimSJ，AhnJW，KimH，etal.Twoβ-strandsofRAGEparticipatein the recognition and transport of amyloid-β peptide across the blood brainbarrier.BiochemBiophysResCommun，2013，439（2）：252-257.
|
| ［10］ |
Martiskainen H，Haapasalo A，Kurkinen KM，et al. Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease. Expert Opin TherTargets，2013，17（7）：781-794.
|
| ［11］ |
Bell RD，Sagare AP，Friedman AE，et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.J Cereb BloodFlowMetab，2007，27（5）：909-918.
|
| ［12］ |
JeynesB，ProviasJ.AninvestigationintotheroleofP-glycoprotein in Alzheimer's disease lesion pathogenesis. Neurosci Lett，2011，487（3）：389-393.
|
| ［13］ |
Utter S，Tamboli IY，Walter J，et al.Cerebral small vessel diseaseinduced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid b-protein in perivascular astrocytes.JNeuropatholExpNeurol，2008，67（9）：842-856.
|
| ［14］ |
Deane R，Sagare A，Hamm K，et al.apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.J Clin Invest，2008，118（12）：4002-4013.
|
| ［15］ |
Jiang Q，Lee CY，Mandrekar S，et al.ApoE promotes the proteolytic degradationofAbeta，Neuron，2008，58（5）：681-693.
|
| ［16］ |
Attems J，Jellinger KA，Lintner F.Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloidangiopathy.ActaNeuropathol，2005，110（3）：222-231.
|
| ［17］ |
Pettersen JA，Sathiyamoorthy G，Gao FQ，et al. Microbleed topography，leukoaraiosis，and cognition in probable Alzheimer disease from the Sunnybrook dementia study.Arch Neurol，2008，65（6）：790-795.
|
| ［18］ |
Greenberg SM，Gurol ME，Rosand J，et al. Amyloid angiopathyrelated vascular cognitive impairment.Stroke，2004，35（11 Suppl 1）：2616-2619.
|
| ［19］ |
JabłońskiM，MaciejewskiR，JanuszewskiS，etal.Oneyearfollowup in ischemic brain injury and the role of Alzheimer factors. Physiol Res，2011，60（Suppl1）：S113-119.
|
| ［20］ |
de la Torre JC. The vascular hypothesis of Alzheimer’s disease：bench to bedside and beyond.Neurodegener Dis，2010，7（1-3）：116-121.
|
| ［21］ |
Formichi P，Parnetti L，Radi E，et al. CSF biomarkers profile in CADASIL-A model of pure vascular dementia： Usefulness in differential diagnosis in the dementia disorder.Int J Alzheimers Dis，2010，18;2010.pii：959257.
|
| ［22］ |
Kalback W，Esh C，Castano EM，et al. Atherosclerosis，vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer’sdisease.NeurolRes，2004，26（5）：525-539.
|
| ［23］ |
vanOijenM，deJongFJ，WittemanJC，etal.Atherosclerosisand risk fordementia.AnnNeurol，2007，61（5）：403-410.
|
| ［24］ |
Debette S，Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging： systematic reviewandmeta-analysis.BMJ，2010，341：c3666.
|
| ［25］ |
Sardi F，Fassina L，Venturini L，et al. Alzheimer's disease，autoimmunity and inflammation. The good，the bad and the ugly.AutoimmunRev，2011，11（2）：149-153.
|
| ［26］ |
Ravaglia G，Forti P，Maioli F，et al.Homocysteine and folate as risk factorsfordementiaandAlzheimerdisease.AmJClinNutr，2005，82（3）：636-643.
|
| ［27］ |
Lehmann M，Regland B，Blennow K，et al.Vitamin B12-B6-folate treatment improves bloodbrain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement GeriatrCognDisord，2003，16（3）：145-150.
|
| ［28］ |
SabbaghMN，AgroA，Bell J，et al.PF-04494700，an oral inhibitor of receptorfor advanced glycation end products（RAGE），in Alzheimer disease.AlzheimerDisAssocDisord，2011，25（3）：206-212.
|
| ［29］ |
Paganetti P，Antoniello K，Devraj K，et al. Increased Efflux of Amyloid-β Peptides through the Blood-Brain Barrier by Muscarinic AcetylcholineReceptorInhibitionReducesPathologicalPhenotypes in Mouse Models of Brain Amyloidosis.J Alzheimers Dis，2013 Sep 26.［Epubaheadofprint］
|
| ［30］ |
Birks J.Cholinesterase inhibitors for Alzheimer’s disease.Cochrane DatabaseSystRev，2006，25（1）D005593.
|
| ［31］ |
Bär KJ，Boettger MK，Seidler N，et al.Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia duetocerebralmicroangiopathy.Stroke，2007，38（12）：3186-92.
|
| ［32］ |
Rosengarten B，Paulsen S，Molnar S，et al.Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimerpatients.JNeurol，2006，253（1）：58-64.
|
| ［33］ |
Claassen JA，Jansen RW.Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders：the cholinergic-vascular hypothesis.J Gerontol A Biol Sci MedSci，2006，61（3）：267-271.
|